Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
464
Completed, industry sponsors, Ophthalmology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed464
464 trials
Showing 1 to 25, recently updated first.
- Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03850782 · 515 participants · Start Feb 28, 2019 · Primary completion Aug 8, 2025
Drug: Bimatoprost (SR) · For: Open-Angle Glaucoma; Ocular Hypertension
Sites: Sun City, Arizona; Huntington Beach, California; Irvine, California · 108 sites in all
- A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT06104124 · 651 participants · Start Jan 24, 2024 · Primary completion Jul 23, 2026
Drug: Dazodalibep; Placebo · For: Sjogren's Syndrome
Sites: Avondale, Arizona; Chandler, Arizona; Flagstaff, Arizona · 206 sites in all
- An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDPivotal-lookingCompleted
Apellis Pharmaceuticals, Inc.Industry
NCT04770545 · 792 participants · Start Mar 4, 2021 · Primary completion Sep 5, 2025
Drug: PEGCETACOPLAN (APL-2) · For: Geographic Atrophy Secondary to Age-related Macular Degeneration
Sites: Phoenix, Arizona; Bakersfield, California; Campbell, California · 175 sites in all
- TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic GlaucomaPivotal-lookingCompleted
Tarsier PharmaIndustry
NCT05042609 · 142 participants · Start Sep 20, 2021 · Primary completion Jun 29, 2023
Drug: TRS01; FDA approved steroid eye drop (masked) · For: Non-infectious Anterior Uveitis; Uveitic Glaucoma
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 30 sites in all
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2Pivotal-lookingCompleted
ReGenTree, LLCIndustry
NCT02974907 · 601 participants · Start Nov 2016 · Primary completion Sep 2017
Drug: RGN-259; Placebo · For: Dry Eye Syndrome
Sites: Phoenix, Arizona; Newport Beach, California; Colorado Springs, Colorado · 10 sites in all
- Clinical Study to Evaluate PRO-169 for Diabetic Macular EdemaPivotal-lookingCompleted
Laboratorios Sophia S.A de C.V.Industry
NCT05217680 · 509 participants · Start May 24, 2021 · Primary completion Aug 18, 2025
Drug: Bevacizumab; Lucentis® · For: Diabetic Macular Edema
Sites: Mexico City, Mexico
- A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular EdemaPivotal-lookingCompleted
Incepta Pharmaceuticals LtdIndustry
NCT06305416 · 70 participants · Start Mar 30, 2024 · Primary completion Mar 10, 2026
Drug: Ranibizumab 10mg/ml Injection; Lucentis · For: Diabetic Macular Edema; Diabetic Retinopathy; Macular Edema and 3 more
Sites: Dhaka, Bangladesh
- Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR GenePivotal-lookingCompleted
MeiraGTx Ocular UK LtdIndustry
NCT04671433 · 105 participants · Start Dec 4, 2020 · Primary completion Sep 30, 2024
Drug: Genetic: AAV5-hRKp.RPGR; Genetic: AAV5-hRKp.RPGR · For: X-Linked Retinitis Pigmentosa
Sites: La Jolla, California; Los Angeles, California; Palo Alto, California · 28 sites in all
- A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseasePivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT07284381 · 261 participants · Start Dec 15, 2025 · Primary completion Aug 21, 2026
Drug: ABBV-444; REFRESH OPTIVE UD · For: Dry Eye Disease
Sites: Dothan, Alabama; Chandler, Arizona; Azusa, California · 20 sites in all
- Safety Study of Tivanisiran to Treat Dry EyePivotal-lookingCompleted
Sylentis, S.A.Industry
NCT05310422 · 301 participants · Start Mar 24, 2022 · Primary completion Oct 11, 2023
Drug: Tivanisiran sodium ophthalmic solution; Vehicle ophthalmic solution · For: Dry Eye Disease
Sites: Chandler, Arizona; Phoenix, Arizona; Glendale, California · 25 sites in all
- Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3Pivotal-lookingCompleted
ReGenTree, LLCIndustry
NCT03937882 · 700 participants · Start May 24, 2019 · Primary completion Nov 8, 2020
Drug: RGN-259; Placebo · For: Dry Eye Syndromes; Dry Eye
Sites: Phoenix, Arizona; Newport Beach, California; Colorado Springs, Colorado · 20 sites in all
- Extension Study of MYL-1701P-3001 for Safety and EfficacyPivotal-lookingCompleted
Mylan Pharmaceuticals IncIndustry
NCT04674800 · 52 participants · Start Nov 23, 2020 · Primary completion Apr 20, 2022
Drug: MYL-1701P, a proposed biosimilar to Eylea · For: Diabetic Macular Edema
Sites: Hyderabad, India; Visakhapatnam, India; Ahmedabad, India · 15 sites in all
- A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)Pivotal-lookingCompleted
Outlook Therapeutics, Inc.Industry
NCT03834753 · 228 participants · Start Jun 25, 2019 · Primary completion Jun 7, 2021
Drug: bevacizumab; ranibizumab · For: Age-related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration
Sites: Tucson, Arizona; Arcadia, California; Beverly Hills, California · 50 sites in all
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Qlaris Bio, Inc.Industry
NCT07354516 · 64 participants · Start Mar 18, 2026 · Primary completion Jul 22, 2026
Drug: Latanoprost (0.005%) · For: OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension
Sites: Largo, Florida
- Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseasePivotal-lookingCompleted
Belite Bio, IncIndustry
NCT05244304 · 104 participants · Start Mar 28, 2022 · Primary completion Aug 4, 2025
Drug: Tinlarebant; Placebo · For: Stargardt Disease 1
Sites: Palo Alto, California; Minneapolis, Minnesota; Salt Lake City, Utah · 19 sites in all
- A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)Pivotal-lookingCompleted
Outlook Therapeutics, Inc.Industry
NCT06190093 · 400 participants · Start Jan 24, 2024 · Primary completion Nov 7, 2024
Drug: bevacizumab; ranibizumab · For: Neovascular Age-related Macular Degeneration; Age-Related Macular Degeneration; Wet Macular Degeneration
Sites: Arcadia, California; Bakersfield, California; Beverly Hills, California · 61 sites in all
- A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal DisordersPivotal-lookingCompleted
Outlook Therapeutics, Inc.Industry
NCT04516278 · 197 participants · Start Oct 1, 2020 · Primary completion Feb 10, 2021
Drug: bevacizumab · For: Age-related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration and 2 more
Sites: Tucson, Arizona; Beverly Hills, California; Glendale, California · 20 sites in all
- Long-term Safety and Efficacy Extension Trial of Bimatoprost SRPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03891446 · 455 participants · Start Mar 27, 2019 · Primary completion Jun 19, 2026
Drug: Bimatoprost SR · For: Open-Angle Glaucoma; Ocular Hypertension
Sites: Dothan, Alabama; Chandler, Arizona; Phoenix, Arizona · 124 sites in all
- Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT05350072 · 275 participants · Start Jul 28, 2022 · Primary completion May 7, 2025
Drug: VAY736 · For: Sjogren Syndrome
Sites: Van Nuys, California; Tamarac, Florida; Indianapolis, Indiana · 77 sites in all
- Study of Rebamipide Eye Drops to Treat Dry EyePivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00201955 · 762 participants · Start May 1, 2004 · Primary completion Jul 1, 2006
Drug: Rebamipide 1%; Rebamipide 2% and 1 more · For: Keratoconjunctivitis Sicca
Sites: Birmingham, Alabama; Flagstaff, Arizona; Little Rock, Arkansas · 60 sites in all
- A 1-Year Study in Multiple Clinics Testing Rebamipide Eye Drops for Dry Eye Compared With a PlaceboPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00201981 · 755 participants · Start May 1, 2004 · Primary completion Feb 1, 2007
Drug: Rebamipide 1%; Rebamipide 2% and 1 more · For: Keratoconjunctivitis Sicca
Sites: Birmingham, Alabama; Glendale, Arizona; Peoria, Arizona · 63 sites in all
- Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05989126 · 35 participants · Start Apr 15, 2024 · Primary completion May 31, 2024
Drug: aflibercept 8 mg PFS · For: Diabetic Macular Edema (DME); Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Bellaire, Texas; The Woodlands, Texas
- Avacincaptad Pegol Open-Label Extension for Patients With Geographic AtrophyPivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05536297 · 278 participants · Start Sep 26, 2022 · Primary completion Apr 10, 2025
Drug: avacincaptad pegol · For: Geographic Atrophy; Age-Related Macular Degeneration
Sites: Campbell, California; Fresno, California; Fullerton, California · 117 sites in all
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)Pivotal-lookingCompleted
OculisIndustry
NCT05066997 · 552 participants · Start Oct 19, 2021 · Primary completion Apr 10, 2026
Drug: Dexamethasone ophthalmic suspension (OCS-01); Vehicle · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Springdale, Arkansas; Beverly Hills, California · 52 sites in all
- Safety and Efficacy of BRM421 for Dry Eye Syndrome TreatmentPivotal-lookingCompleted
BRIM Biotechnology Inc.Industry
NCT04343287 · 220 participants · Start Jan 15, 2020 · Primary completion Jun 23, 2020
Drug: BRM421; Placebo · For: Dry Eye Syndrome
Sites: Newport Beach, California; Indianapolis, Indiana; Andover, Massachusetts · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.